Quick Answer
Medicus Pharma Ltd. reported R&D Expense of $7.72 million for fiscal year 2025.
Medicus Pharma Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.72M | +118.9% |
| 2024 | $3.53M | +1722.4% |
| 2023 | $193.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.68M | +198.6% | +17.0% |
| June 30, 2025 | $1.44M | +12.7% | -28.2% |
| March 31, 2025 | $2.01M | +524.3% | +255.6% |
| September 30, 2024 | $564.1K | — | -55.8% |
| June 30, 2024 | $1.28M | — | +297.4% |
| March 31, 2024 | $321.4K | — | — |
- Medicus Pharma Ltd. showed an increase of +118.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Medicus Pharma Ltd.’s r&d expense has grown by 3888.8% (from $193.6 thousand to $7.72 million).
- The most recent figure is from Medicus Pharma Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: